You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Last Updated: February 22, 2020

DrugPatentWatch Database Preview

LUCENTIS Drug Profile

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Summary for Tradename: LUCENTIS

Patents:	175
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for LUCENTIS

Recent Clinical Trials for LUCENTIS

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Wake Forest University Health Sciences	Phase 4
Sun Yat-sen University	Phase 4
Second Military Medical University	Phase 3

See all LUCENTIS clinical trials

Pharmacology for LUCENTIS

Mechanism of Action	Vascular Endothelial Growth Factor Receptor Inhibitors Vascular Endothelial Growth Factor-directed Antibody Interactions

Patent Text Search: US Patents for LUCENTIS

These patents were identified by searching patent claims

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Genentech	LUCENTIS	ranibizumab	INJECTABLE; INJECTION	125156	001	2006-06-30	Start Trial	Avalanche Australia Pty Ltd. (Southbank, AU)	2032-05-15	RX		search
Genentech	LUCENTIS	ranibizumab	INJECTABLE; INJECTION	125156	001	2006-06-30	Start Trial	SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL)	2033-03-11	RX		search
Genentech	LUCENTIS	ranibizumab	INJECTABLE; INJECTION	125156	001	2006-06-30	Start Trial	Pharmacyclics LLC (Sunnyvale, CA)	2033-08-12	RX		search
Genentech	LUCENTIS	ranibizumab	INJECTABLE; INJECTION	125156	001	2006-06-30	Start Trial	Bayer Pharma Aktiengesellschaft (Berlin, DE)	2034-11-25	RX		search
Genentech	LUCENTIS	ranibizumab	INJECTABLE; INJECTION	125156	001	2006-06-30	Start Trial	Agency for Science, Technology and Research (Singapore, SG)	2034-05-09	RX		search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

International Patents for LUCENTIS

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
European Patent Office	2990049	Start Trial
United Kingdom	0902572	Start Trial
Russian Federation	2008140947	Start Trial
China	103140216	Start Trial
Hong Kong	1185513	Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey

Boehringer Ingelheim

Johnson and Johnson

Dow

AstraZeneca

Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.